$2.25+0.05|(+2.27%)

Analyst Recommendation Trends

Wall Street analyst consensus for SEER over the last few months:

2026-09-01
Buy: 5
S.Buy: 2
Hold: 1
Sell: 0
2026-08-01
Buy: 5
S.Buy: 2
Hold: 1
Sell: 0
2026-07-01
Buy: 5
S.Buy: 2
Hold: 1
Sell: 0
2026-06-01
Buy: 5
S.Buy: 2
Hold: 1
Sell: 0

Latest SEER News

Seer and Nanyang Technological University to Present Early Findings from Landmark PRECISE-SG100K Proteomics Study at HUPO 2026

John Chambers, PhD, and Nilanjana Sadhu, PhD, to share early insights from pioneering population-scale proteomic study of 10,000 participants in SingaporeREDWOOD CITY, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) today announced that researchers from Nanyang Technological University will present early findings from the PRECISE-SG100K study at the 2026 Human Proteome Organization (HUPO) World Congress, taking place September 27 to October 1 at the Suntec Singapore Conventi

Yahoo9/23/2026

Seer Announces CFO Transition

REDWOOD CITY, Calif., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that David Horn, the Company’s President, Chief Financial Officer and Treasurer, will depart Seer effective October 1, 2026, to pursue a new opportunity at a private company. Charles Endweiss, who has been Seer’s Vice President, Financial Planning & Analysis, will serve as Treasurer, principal financia

Yahoo9/21/2026

Seer Announces Resignation Of President And CFO David Horn Effective October 1; Appoints Charles Endweiss As Principal Financial Officer

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001726445/000119312526395523/d110986d8k.htm

Benzinga9/18/2026

Seer Surpasses 100 Peer-Reviewed Customer Publications, Validating a New Era of Deep Proteomics at Scale

Six years after Seer’s foundational Nature Communications paper, researchers across three continents have built a growing body of evidence demonstrating the power of deep, unbiased proteomics across genetics, aging, disease biology and population healthREDWOOD CITY, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a pioneer in deep, unbiased proteomics, today announced that its Proteograph® Product Suite has been used by researchers in more than 100 peer-reviewed scientific

Yahoo9/16/2026

Radoff-JEC Group Calls on Meeta Gulyani to Immediately Resign from Seer, Inc.’s Board of Directors

HOUSTON, September 04, 2026--Bradley L. Radoff and Michael Torok, who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ: SEER), today issued the following open letter to director Meeta Gulyani.

Yahoo9/4/2026

Related Stocks (Peers)

Companies operating in similar sectors to SEER:

Recent Insider Transactions

DateNameShares ChangedPriceValue
2026-08-18Horn David R.-7,309$2.0262$14,809
2026-07-28Gulyani Meeta+25,000--
2026-07-28Gulyani Meeta+16,500--
2026-07-28Ro Isaac+18,750--
2026-07-28Ro Isaac+12,375--
2026-07-28Nishar Dipchand+25,000--
2026-07-28Nishar Dipchand+16,500--
2026-07-28Roelofs Nicolas H PHD+25,000--
2026-07-28Roelofs Nicolas H PHD+16,500--
2026-07-28LANGER ROBERT+25,000--
2026-07-28LANGER ROBERT+16,500--
2026-07-28MCGUIRE TERRANCE+25,000--
2026-07-28MCGUIRE TERRANCE+16,500--
2026-07-08Nishar Dipchand-10,660$2.1825$23,265
2026-05-20Horn David R.-7,303$1.6913$12,352
2026-05-08Bazarko Anthony R.+225,000--
2026-05-08Bazarko Anthony R.+75,000--
2026-02-18Horn David R.-7,743$1.9949$15,447
2026-02-18Farokhzad Omid-24,385$1.9949$48,646
2026-02-03Horn David R.+119,000--
2026-02-03Horn David R.+79,000--
2026-02-03Farokhzad Omid+512,000--
2026-02-03Farokhzad Omid+697,162--
2025-12-09Farokhzad Omid-2,117,138--
2025-12-09Farokhzad Omid-1,438,057--
2025-12-09Farokhzad Omid+2,117,138--
2025-12-09Farokhzad Omid+1,438,057--
2025-12-09MCGUIRE TERRANCE-4,088--
2025-12-09MCGUIRE TERRANCE+4,088--
2025-11-19Horn David R.-6,797$1.9714$13,400
2025-11-19Farokhzad Omid-33,838$1.9714$66,708